51
|
Gondran-Tellier B, Boissier R, Lyonnet L, Simoncini S, Meunier M, Francois P, Legris T, Burtey S, Dignat-Georges F, Karsenty G, Lechevallier E, Sabatier F, Pau P. La graisse péri-rénale issue des prélèvements d’organes : une source non invasive de cellules endothéliales comme modèle d’évaluation du vieillissement vasculaire et de l’alloimmunogénicité des transplants marginaux. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
52
|
Bobot M, Kauffman M, Daniel L, Knefati Y, Moranne O, Burtey S, Zandotti C, Jourde-Chiche N. Infection à Parvovirus B19 et atteintes rénales : description de 4 cas, et étude du statut sérologique et virémique de 100 patients adultes ayant bénéficié d’une ponction biopsie rénale. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
53
|
Bobot M, Hache G, Fernandez S, Balasse L, Brige P, Chopinet S, Thomas L, Mckay N, Burtey S, Guillet B. L’atteinte cognitive est associée à une rupture de la barrière hémato-encéphalique et aux concentrations d’indoxyl sulfate dans deux modèles de maladie rénale chronique chez le rat. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
54
|
Bobot M, Hache G, Fernandez S, Balasse L, Brige P, Chopinet S, Thomas L, Mckay N, Burtey S, Guillet B. FO029COGNITIVE IMPAIRMENT WAS ASSOCIATED WITH BRAIN-BLOOD BARRIER PERMEABILITY IN TWO MODELS OF CHRONIC KIDNEY DISEASE IN RATS. Nephrol Dial Transplant 2019. [DOI: 10.1093/ndt/gfz107.fo029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Mickaël Bobot
- La Timone (Aix-Marseille Université), Marseille, France
| | | | - Samatha Fernandez
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | - Laure Balasse
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | - Pauline Brige
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | - Sophie Chopinet
- Faculté de Médecine Timone (Aix-Marseille University), Marseille, France
| | | | | | | | | |
Collapse
|
55
|
Affiliation(s)
- Christine Maynié-François
- Collège Universitaire de Médecine Générale, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
| | - Stéphane Burtey
- Aix Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRA), Centre de Recherche en Cardio-Vasculaire et Nutrition (C2VN), Marseille, France.,Centre de Néphrologie et Transplantation Rénale, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| |
Collapse
|
56
|
Sallée M, Burtey S. Myeloma cast nephropathy: the dusk of high cutoff haemodialysis. Lancet Haematol 2019; 6:e174-e176. [PMID: 30872076 DOI: 10.1016/s2352-3026(19)30044-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 02/27/2019] [Indexed: 10/27/2022]
Affiliation(s)
- Marion Sallée
- Nephrology and Renal Transplantation Centre, Conception Hospital, Marseille, France; Centre Recherche en Cardiovasculaire et Nutrition (C2VN), Aix-Marseille University, INSERM, INRA (French National Institute for Agricultural Research), Marseille, France
| | - Stéphane Burtey
- Nephrology and Renal Transplantation Centre, Conception Hospital, Marseille, France; Centre Recherche en Cardiovasculaire et Nutrition (C2VN), Aix-Marseille University, INSERM, INRA (French National Institute for Agricultural Research), Marseille, France.
| |
Collapse
|
57
|
Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019. [PMID: 30607032 DOI: 10.1038/s4158] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
Abstract
The kidney harbours different types of endothelia, each with specific structural and functional characteristics. The glomerular endothelium, which is highly fenestrated and covered by a rich glycocalyx, participates in the sieving properties of the glomerular filtration barrier and in the maintenance of podocyte structure. The microvascular endothelium in peritubular capillaries, which is also fenestrated, transports reabsorbed components and participates in epithelial cell function. The endothelium of large and small vessels supports the renal vasculature. These renal endothelia are protected by regulators of thrombosis, inflammation and complement, but endothelial injury (for example, induced by toxins, antibodies, immune cells or inflammatory cytokines) or defects in factors that provide endothelial protection (for example, regulators of complement or angiogenesis) can lead to acute or chronic renal injury. Moreover, renal endothelial cells can transition towards a mesenchymal phenotype, favouring renal fibrosis and the development of chronic kidney disease. Thus, the renal endothelium is both a target and a driver of kidney and systemic cardiovascular complications. Emerging therapeutic strategies that target the renal endothelium may lead to improved outcomes for both rare and common renal diseases.
Collapse
Affiliation(s)
- Noemie Jourde-Chiche
- Aix-Marseille University, Centre de Nephrologie et Transplantation Renale, AP-HM Hopital de la Conception, Marseille, France.
- Aix-Marseille University, C2VN, INSERM 1263, Institut National de la Recherche Agronomique (INRA) 1260, Faculte de Pharmacie, Marseille, France.
| | - Fadi Fakhouri
- Centre de Recherche en Transplantation et Immunologie, INSERM, Université de Nantes and Department of Nephrology, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Laetitia Dou
- Aix-Marseille University, C2VN, INSERM 1263, Institut National de la Recherche Agronomique (INRA) 1260, Faculte de Pharmacie, Marseille, France
| | - Jeremy Bellien
- Department of Pharmacology, Rouen University Hospital and INSERM, Normandy University, Université de Rouen Normandie, Rouen, France
| | - Stéphane Burtey
- Aix-Marseille University, Centre de Nephrologie et Transplantation Renale, AP-HM Hopital de la Conception, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, Institut National de la Recherche Agronomique (INRA) 1260, Faculte de Pharmacie, Marseille, France
| | - Marie Frimat
- Université de Lille, INSERM, Centre Hospitalier Universitaire de Lille, U995, Lille Inflammation Research International Center (LIRIC), Lille, France
- Nephrology Department, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Pierre-André Jarrot
- Aix-Marseille University, C2VN, INSERM 1263, Institut National de la Recherche Agronomique (INRA) 1260, Faculte de Pharmacie, Marseille, France
- Assistance Publique-Hôpitaux de Marseille, Service de Médecine Interne et d'Immunologie Clinique, Hôpital de La Conception, Marseille, France
| | - Gilles Kaplanski
- Aix-Marseille University, C2VN, INSERM 1263, Institut National de la Recherche Agronomique (INRA) 1260, Faculte de Pharmacie, Marseille, France
- Assistance Publique-Hôpitaux de Marseille, Service de Médecine Interne et d'Immunologie Clinique, Hôpital de La Conception, Marseille, France
| | - Moglie Le Quintrec
- Centre Hospitalier Universitaire de Lapeyronie, Département de Néphrologie Dialyse et Transplantation Rénale, Montpellier, France
- Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France
| | - Vincent Pernin
- Centre Hospitalier Universitaire de Lapeyronie, Département de Néphrologie Dialyse et Transplantation Rénale, Montpellier, France
- Institute for Regenerative Medicine and Biotherapy (IRMB), Montpellier, France
| | - Claire Rigothier
- Tissue Bioengineering, Université de Bordeaux, Bordeaux, France
- Service de Néphrologie Transplantation, Dialyse et Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Marion Sallée
- Aix-Marseille University, Centre de Nephrologie et Transplantation Renale, AP-HM Hopital de la Conception, Marseille, France
- Aix-Marseille University, C2VN, INSERM 1263, Institut National de la Recherche Agronomique (INRA) 1260, Faculte de Pharmacie, Marseille, France
| | - Veronique Fremeaux-Bacchi
- Assistance Publique-Hôpitaux de Paris, Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
| | - Dominique Guerrot
- Normandie Université, Université de Rouen Normandie, Rouen University Hospital, Department of Nephrology, Rouen, France
| | - Lubka T Roumenina
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France.
- Sorbonne Universités, Paris, France.
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
58
|
Daviet F, Rouby F, Poullin P, Moussi‐Francès J, Sallée M, Burtey S, Mancini J, Duffaud F, Sabatier R, Pourroy B, Grandvuillemin A, Grange S, Frémeaux‐Bacchi V, Coppo P, Micallef J, Jourde‐Chiche N. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol 2019; 85:403-412. [PMID: 30394581 PMCID: PMC6339967 DOI: 10.1111/bcp.13808] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Revised: 10/09/2018] [Accepted: 10/21/2018] [Indexed: 12/14/2022] Open
Abstract
AIMS Gemcitabine has been associated with thrombotic microangiopathy (TMA). We conducted a national retrospective study of gemcitabine-associated TMA (G-TMA). METHODS From 1998 to 2015, all cases of G-TMA reported to the French Pharmacovigilance Network and the French TMA Reference Center, and cases explored for complement alternative pathway abnormalities, were analysed. RESULTS G-TMA was diagnosed in 120 patients (median age 61.5 years), after a median of 210 days of treatment, and a cumulative dose of 12 941 mg m-2 . Gemcitabine indications were: pancreatic (52.9%), pulmonary (12.6%) and breast (7.6%) cancers, metastatic in 34.2% of cases. Main symptoms were oedema (56.7%) and new-onset or exacerbated hypertension (62.2%). Most patients presented with haemolytic anaemia (95.6%) and thrombocytopenia (74.6%). Acute kidney injury was reported in 97.4% and dialysis was required in 27.8% of patients. Treatment consisted of: plasma exchange (PE; 39.8%), fresh frozen plasma (21.4%), corticosteroids (15.3%) and eculizumab (5.1%). A complete remission of TMA was obtained in 42.1% of patients and haematological remission in 23.1%, while 34.7% did not improve. The survival status was known for 52 patients, with 29 deaths (54.7%). Patients treated with PE, despite a more severe acute kidney injury, requiring dialysis more frequently, displayed comparable rates of remission, but with more adverse events. No abnormality in complement alternative pathway was documented in patients explored. CONCLUSION This large cohort confirms the severity of G-TMA, associated with severe renal failure and death. Oedema and hypertension could be monitored in patients treated with gemcitabine to detect early TMA. The benefit of PE or eculizumab deserves further investigation.
Collapse
Affiliation(s)
- Florence Daviet
- Department of NephrologyAix‐Marseille UniversityAP‐HM Hôpital de la ConceptionMarseilleFrance
| | - Franck Rouby
- Department of Clinical Pharmacology and Pharmacovigilance, Regional Centre of PharmacovigilanceAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
- Department of Clinical Pharmacology and PharmacovigilanceAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
- INSERM UMR_S 1106, INS, Inst Neurosciences SystemsAix Marseille UniversityMarseilleFrance
| | - Pascale Poullin
- Department of Apheresis, Regional Reference Center for Thrombotic MicroangiopathyAix‐Marseille UniversityAP‐HM Hôpital de la ConceptionMarseilleFrance
| | - Julie Moussi‐Francès
- Department of NephrologyAix‐Marseille UniversityAP‐HM Hôpital de la ConceptionMarseilleFrance
| | - Marion Sallée
- Department of NephrologyAix‐Marseille UniversityAP‐HM Hôpital de la ConceptionMarseilleFrance
- Aix‐Marseille UniversityC2VN, INSERM 1263, INRA 1260MarseilleFrance
| | - Stéphane Burtey
- Department of NephrologyAix‐Marseille UniversityAP‐HM Hôpital de la ConceptionMarseilleFrance
- Aix‐Marseille UniversityC2VN, INSERM 1263, INRA 1260MarseilleFrance
| | - Julien Mancini
- Department of Public HealthAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
| | - Florence Duffaud
- Department of Clinical OncologyAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
| | - Renaud Sabatier
- Department of Clinical Oncology, Institut Paoli Calmettes, Laboratory of Molecular OncologyAix‐Marseille UniversityCRCM INSERM UMR 1068MarseilleFrance
| | - Bertrand Pourroy
- Department of Parmacy, OncoPharma UnitAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
| | | | - Steven Grange
- Medical intensive care unit, Regional Center for Thrombotic Microangiopathy, Hôpital Charles NicolleRouen University HospitalRouenFrance
| | | | - Paul Coppo
- Department of Hematology, French Reference Center for Thrombotic Microangiopathy (www.cnr‐mat.fr)Paris 6 UniversityParisFrance
| | - Joëlle Micallef
- Department of Clinical Pharmacology and Pharmacovigilance, Regional Centre of PharmacovigilanceAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
- Department of Clinical Pharmacology and PharmacovigilanceAix‐Marseille UniversityAP‐HM Hôpital de la TimoneMarseilleFrance
- INSERM UMR_S 1106, INS, Inst Neurosciences SystemsAix Marseille UniversityMarseilleFrance
| | - Noémie Jourde‐Chiche
- Department of NephrologyAix‐Marseille UniversityAP‐HM Hôpital de la ConceptionMarseilleFrance
- Aix‐Marseille UniversityC2VN, INSERM 1263, INRA 1260MarseilleFrance
| |
Collapse
|
59
|
Chiche L, Seguier J, Gentille S, Dussol B, Burtey S, Halfon P, Jouve E, Jourde-Chiche N. Association inattendue entre la qualité de vie et les signatures interféron transcriptomiques sanguines au cours du lupus érythémateux systémique. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
60
|
Chevalier T, Burtey S, Barlesi F. Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies. J Thorac Oncol 2018; 13:e231-e232. [PMID: 30368416 DOI: 10.1016/j.jtho.2018.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 07/02/2018] [Accepted: 07/02/2018] [Indexed: 11/26/2022]
Affiliation(s)
- Thomas Chevalier
- Marseille Early Phases Cancer Center CLIP2, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
| | - Stéphane Burtey
- Department of Nephrology and Kidney Transplantation, Assistance Publique Hôpitaux de Marseille, and INSERM, INRA, C2VN, Aix Marseille University, Marseille, France
| | - Fabrice Barlesi
- Marseille Early Phases Cancer Center CLIP2, and Department of Nephrology and Kidney Transplantation, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France
| |
Collapse
|
61
|
Ernest V, Cammilleri S, Amabile P, Fedi M, Burtey S, Von Kotze C, Pelletier M, Moal V, Guedj E, Perron C, Boustani R, Berland Y, Brunet P, Raoult D, Fournier PE, Jourde-Chiche N. Hemodialysis vascular graft as a focus of persistent Q fever. Infection 2018; 46:881-884. [DOI: 10.1007/s15010-018-1206-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 08/23/2018] [Indexed: 12/14/2022]
|
62
|
Addi T, Poitevin S, McKay N, El Mecherfi KE, Kheroua O, Jourde-Chiche N, de Macedo A, Gondouin B, Cerini C, Brunet P, Dignat-George F, Burtey S, Dou L. Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Arch Toxicol 2018; 93:121-136. [PMID: 30324315 DOI: 10.1007/s00204-018-2328-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Accepted: 10/09/2018] [Indexed: 12/11/2022]
Abstract
Chronic kidney disease (CKD) is associated with high risk of thrombosis. Indole-3 acetic acid (IAA), an indolic uremic toxin, induces the expression of tissue factor (TF) in human umbilical vein endothelial cells (HUVEC) via the transcription factor aryl hydrocarbon receptor (AhR). This study aimed to understand the signaling pathways involved in AhR-mediated TF induction by IAA. We incubated human endothelial cells with IAA at 50 µM, the maximal concentration found in patients with CKD. IAA induced TF expression in different types of human endothelial cells: umbilical vein (HUVEC), aortic (HAoEC), and cardiac-derived microvascular (HMVEC-C). Using AhR inhibition and chromatin immunoprecipitation experiments, we showed that TF induction by IAA in HUVEC was controlled by AhR and that AhR did not bind to the TF promoter. The analysis of TF promoter activity using luciferase reporter plasmids showed that the NF-κB site was essential in TF induction by IAA. In addition, TF induction by IAA was drastically decreased by an inhibitor of the NF-κB pathway. IAA induced the nuclear translocation of NF-κB p50 subunit, which was decreased by AhR and p38MAPK inhibition. Finally, in a cohort of 92 CKD patients on hemodialysis, circulating TF was independently related to serum IAA in multivariate analysis. In conclusion, TF up-regulation by IAA in human endothelial cells involves a non-genomic AhR/p38 MAPK/NF-κB pathway. The understanding of signal transduction pathways related to AhR thrombotic/inflammatory pathway is of interest to find therapeutic targets to reduce TF expression and thrombotic risk in patients with CKD.
Collapse
Affiliation(s)
- Tawfik Addi
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
- Département de Biologie, Université d'Oran 1 Ahmed Benbella, LPNSA, Oran, Algeria
| | - Stéphane Poitevin
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
| | - Nathalie McKay
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
| | - Kamel Eddine El Mecherfi
- Département de Biologie, Université d'Oran 1 Ahmed Benbella, LPNSA, Oran, Algeria
- Université Mohamed Boudiaf USTO, Dpt génétique Moléculaire Appliquée (GMA), Oran, Algeria
| | - Omar Kheroua
- Département de Biologie, Université d'Oran 1 Ahmed Benbella, LPNSA, Oran, Algeria
| | - Noémie Jourde-Chiche
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Alix de Macedo
- Service de Pédiatrie-Néonatologie, Hôpital Fondation Saint Joseph, Marseille, France
| | | | - Claire Cerini
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
| | - Philippe Brunet
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Françoise Dignat-George
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
| | - Stéphane Burtey
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Laetitia Dou
- Faculté de pharmacie, Aix-Marseille Université, INSERM, INRA, C2VN, 27 bd Jean Moulin, 13005, Marseille, France.
| |
Collapse
|
63
|
Addi T, Dou L, Burtey S. Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease. Toxins (Basel) 2018; 10:E412. [PMID: 30322010 PMCID: PMC6215213 DOI: 10.3390/toxins10100412] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 10/09/2018] [Accepted: 10/10/2018] [Indexed: 02/07/2023] Open
Abstract
Patients with chronic kidney disease (CKD) display an elevated risk of thrombosis. Thrombosis occurs in cardiovascular events, such as venous thromboembolism, stroke, and acute coronary syndrome, and is a cause of hemodialysis vascular access dysfunction. CKD leads to the accumulation of uremic toxins, which exerts toxic effects on blood and the vessel wall. Some uremic toxins result from tryptophan metabolization in the gut through the indolic and the kynurenine pathways. An increasing number of studies are highlighting the link between such uremic toxins and thrombosis in CKD. In this review, we describe the thrombotic mechanisms induced by tryptophan-derived uremic toxins (TDUT). These mechanisms include an increase in plasma levels of procoagulant factors, induction of platelet hyperactivity, induction of endothelial dysfunction/ impairment of endothelial healing, decrease in nitric oxide (NO) bioavailability, and production of procoagulant microparticles. We focus on one important prothrombotic mechanism: The induction of tissue factor (TF), the initiator of the extrinsic pathway of the blood coagulation. This induction occurs via a new pathway, dependent on the transcription factor Aryl hydrocarbon receptor (AhR), the receptor of TDUT in cells. A better understanding of the prothrombotic mechanisms of uremic toxins could help to find novel therapeutic targets to prevent thrombosis in CKD.
Collapse
Affiliation(s)
- Tawfik Addi
- Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France.
- LPNSA, Département de Biologie, Université d'Oran 1 Ahmed Benbella, 31000 Oran, Algérie.
| | - Laetitia Dou
- Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France.
| | - Stéphane Burtey
- Aix Marseille University, INSERM, INRA, C2VN, 13005 Marseille, France.
- Centre de Néphrologie et Transplantation Rénale, AP-HM, 13005 Marseille, France.
| |
Collapse
|
64
|
Bobot M, Hache G, Garrigue P, Brunet P, Burtey S, Guillet B. La scintigraphie rénale à l’acide dimercaptosuccinique 99mTc permet d’évaluer le développement de la fibrose interstitielle au cours d’un régime riche en adénine chez le rat. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
65
|
Burtey S, Addi T, Mckay N, Poitevin S, Dou L. Comment aryl hydrocarbon receptor active-t-il l’expression du facteur tissulaire dans l’endothélium humain en réponse à l’indole-3 acétique acide ? Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
66
|
Bataille S, Quinonez K, Buckinx F, Warling X, Krzesinski J, Pottel H, Burtey S, Bruyère O, Cavalier E, Delanaye P. La myostatine et l’IGF1 sont de bons biomarqueurs de la force et de la masse musculaire chez les patients hémodialysés chroniques. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
67
|
Bobot M, Zieleskiewicz L, Burtey S, Jourde-Chiche N, Dussol B, Sallée M, Berland Y, Brunet P, Robert T. Performances diagnostiques de l’échographie pulmonaire et d’un score clinique pour l’évaluation de l’état d’hydratation chez le patient hémodialysé chronique. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
68
|
Bataille S, Quinonez K, Krzesinski JM, Burtey S, Delanaye P. SP650MYOSTATIN: A NEW BIOMARKER OF MUSCLE STRENGTH IN HEMODIALYSIS PATIENTS. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.sp650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Stanislas Bataille
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
- Vascular Research Center of Marseille, Aix-Marseille University, Marseille, France
- Nephrology, Phocean Nephrology Institute, Marseille, France
| | - Kevin Quinonez
- Department of Nephrology, Dialysis, Transplantation, University of Liège (CHU ULg), Liège, Belgium
| | - Jean-Marie Krzesinski
- Department of Nephrology, Dialysis, Transplantation, University of Liège (CHU ULg), Liège, Belgium
| | - Stéphane Burtey
- Vascular Research Center of Marseille, Aix-Marseille University, Marseille, France
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Pierre Delanaye
- Department of Nephrology, Dialysis, Transplantation, University of Liège (CHU ULg), Liège, Belgium
| |
Collapse
|
69
|
Dou L, Poitevin S, Sallée M, Addi T, Gondouin B, McKay N, Denison MS, Jourde-Chiche N, Duval-Sabatier A, Cerini C, Brunet P, Dignat-George F, Burtey S. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. Kidney Int 2018; 93:986-999. [PMID: 29395338 DOI: 10.1016/j.kint.2017.11.010] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Revised: 10/18/2017] [Accepted: 11/09/2017] [Indexed: 11/25/2022]
Abstract
Patients with chronic kidney disease (CKD) are exposed to uremic toxins and have an increased risk of cardiovascular disease. Some uremic toxins, like indoxyl sulfate, are agonists of the transcription factor aryl hydrocarbon receptor (AHR). These toxins induce a vascular procoagulant phenotype. Here we investigated AHR activation in patients with CKD and in a murine model of CKD. We performed a prospective study in 116 patients with CKD stage 3 to 5D and measured the AHR-Activating Potential of serum by bioassay. Compared to sera from healthy controls, sera from CKD patients displayed a strong AHR-Activating Potential; strongly correlated with eGFR and with the indoxyl sulfate concentration. The expression of the AHR target genes Cyp1A1 and AHRR was up-regulated in whole blood from patients with CKD. Survival analyses revealed that cardiovascular events were more frequent in CKD patients with an AHR-Activating Potential above the median. In mice with 5/6 nephrectomy, there was an increased serum AHR-Activating Potential, and an induction of Cyp1a1 mRNA in the aorta and heart, absent in AhR-/- CKD mice. After serial indoxyl sulfate injections, we observed an increase in serum AHR-AP and in expression of Cyp1a1 mRNA in aorta and heart in WT mice, but not in AhR-/- mice. Thus, the AHR pathway is activated both in patients and mice with CKD. Hence, AHR activation could be a key mechanism involved in the deleterious cardiovascular effects observed in CKD.
Collapse
Affiliation(s)
- Laetitia Dou
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France
| | - Stéphane Poitevin
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France
| | - Marion Sallée
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Tawfik Addi
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France
| | - Bertrand Gondouin
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Nathalie McKay
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France
| | - Michael S Denison
- Department of Environmental Toxicology, University of California, Davis, California, USA
| | - Noémie Jourde-Chiche
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Ariane Duval-Sabatier
- Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France; Association des dialysés Provence-Corse, Marseille, France
| | - Claire Cerini
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France
| | - Philippe Brunet
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | | | - Stéphane Burtey
- Aix-Marseille University, INSERM, UMR-S 1076, VRCM, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France.
| |
Collapse
|
70
|
Santana Machado T, Poitevin S, Paul P, McKay N, Jourde-Chiche N, Legris T, Mouly-Bandini A, Dignat-George F, Brunet P, Masereeuw R, Burtey S, Cerini C. Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling. J Am Soc Nephrol 2017; 29:906-918. [PMID: 29222397 DOI: 10.1681/asn.2017030361] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 11/14/2017] [Indexed: 11/03/2022] Open
Abstract
In patients with CKD, not only renal but also, nonrenal clearance of drugs is altered. Uremic toxins could modify the expression and/or activity of drug transporters in the liver. We tested whether the uremic toxin indoxyl sulfate (IS), an endogenous ligand of the transcription factor aryl hydrocarbon receptor, could change the expression of the following liver transporters involved in drug clearance: SLC10A1, SLC22A1, SLC22A7, SLC47A1, SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCB11, ABCC2, ABCC3, ABCC4, ABCC6, and ABCG2 We showed that IS increases the expression and activity of the efflux transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma cells (HepG2) without modifying the expression of the other transporters. This effect depended on the aryl hydrocarbon receptor pathway. Presence of human albumin at physiologic concentration in the culture medium did not abolish the effect of IS. In two mouse models of CKD, the decline in renal function associated with the accumulation of IS in serum and the specific upregulation of Abcb1a in the liver. Additionally, among 109 heart or kidney transplant recipients with CKD, those with higher serum levels of IS needed higher doses of cyclosporin, a P-gp substrate, to obtain the cyclosporin target blood concentration. This need associated with serum levels of IS independent of renal function. These findings suggest that increased activity of P-gp could be responsible for increased hepatic cyclosporin clearance. Altogether, these results suggest that uremic toxins, such as IS, through effects on drug transporters, may modify the nonrenal clearance of drugs in patients with CKD.
Collapse
Affiliation(s)
- Tacy Santana Machado
- Coordination for the Improvement of Higher Education Personnel (CAPES Foundation), Ministry of Education of Brazil, Brasilia, Brazil.,Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France
| | - Stéphane Poitevin
- Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France
| | - Pascale Paul
- Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France
| | - Nathalie McKay
- Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France
| | - Noémie Jourde-Chiche
- Marseille Public University Hospital System (APHM), Conception Hospital, Centre de Néphrologie et Transplantation Rénale, Marseille, France
| | - Tristan Legris
- Marseille Public University Hospital System (APHM), Conception Hospital, Centre de Néphrologie et Transplantation Rénale, Marseille, France
| | - Annick Mouly-Bandini
- Department of Cardiac Surgery, Marseille Public University Hospital System (APHM), La Timone Hospital, Marseille, France
| | - Françoise Dignat-George
- Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France
| | - Philippe Brunet
- Marseille Public University Hospital System (APHM), Conception Hospital, Centre de Néphrologie et Transplantation Rénale, Marseille, France.,European Uraemic Toxin Working Group (EUTox) of The European Society for Artificial Organs (ESAO) endorsed by European Renal Association & European Dialysis and Transplant Assiociation (ERA-EDTA), Krems, Austria; and
| | - Rosalinde Masereeuw
- European Uraemic Toxin Working Group (EUTox) of The European Society for Artificial Organs (ESAO) endorsed by European Renal Association & European Dialysis and Transplant Assiociation (ERA-EDTA), Krems, Austria; and.,Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
| | - Stéphane Burtey
- Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France.,Marseille Public University Hospital System (APHM), Conception Hospital, Centre de Néphrologie et Transplantation Rénale, Marseille, France.,European Uraemic Toxin Working Group (EUTox) of The European Society for Artificial Organs (ESAO) endorsed by European Renal Association & European Dialysis and Transplant Assiociation (ERA-EDTA), Krems, Austria; and
| | - Claire Cerini
- Aix Marseille University, Faculty of Pharmacy, National Institute of Health and Medical Research (INSERM), Vascular Research Center of Marseille (VRCM), Marseille, France;
| |
Collapse
|
71
|
Sallée M, Santana Machado T, Mckay N, Mallmann C, Bouchouareb D, Brunet P, Burtey S. Impact de l’alimentation sur les taux de toxines urémiques. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
72
|
Bataille S, Pelletier M, Sallée M, Berland Y, Mckay N, Duval-Sabatier A, Gentile S, Mouelhi Y, Brunet P, Burtey S. L’indole-3-acétique acide, l’indoxyl sulfate et le para-cresyl sulfate ne sont pas corrélés aux marqueurs de l’anémie des patients hémodialysés chroniques. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
73
|
Bataille S, Landrier J, Pedinelli N, Serveaux M, Darmon P, Burtey S. La concentration plasmatique en rétinol est principalement fonction de la transthyrétine chez les patients hémodialysés. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
74
|
Fages L, Moal V, Boucekine M, Brunet P, Moussi-Francès J, Legris T, Purgus R, Daniel L, Burtey S, Dussol B, Berland Y, Vacher-Coponat H. Suivi à 10 ans d’un essai thérapeutique en transplantation rénale comparant deux stratégies immunosuppressives avec corticoïdes et globuline anti-thymocytes : ciclosporine/azathioprine contre tacrolimus/mycophénolate mofétil. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
75
|
Bataille S, Pelletier M, Sallée M, Berland Y, McKay N, Duval A, Gentile S, Mouelhi Y, Brunet P, Burtey S. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients. BMC Nephrol 2017; 18:251. [PMID: 28747155 PMCID: PMC5530556 DOI: 10.1186/s12882-017-0668-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2017] [Accepted: 07/14/2017] [Indexed: 12/16/2022] Open
Abstract
Background The main reason for anemia in renal failure patients is the insufficient erythropoietin production by the kidneys. Beside erythropoietin deficiency, in vitro studies have incriminated uremic toxins in the pathophysiology of anemia but clinical data are sparse. In order to assess if indole 3-acetic acid (IAA), indoxyl sulfate (IS), and paracresyl sulfate (PCS) -three protein bound uremic toxins- are clinically implicated in end-stage renal disease anemia we studied the correlation between IAA, IS and PCS plasmatic concentrations with hemoglobin and Erythropoietin Stimulating Agents (ESA) use in hemodialysis patients. Methods Between June and July 2014, we conducted an observational cross sectional study in two hemodialysis center. Three statistical approaches were conducted. First, we compared patients treated with ESA and those not treated. Second, we performed linear regression models between IAA, IS, and PCS plasma concentrations and hemoglobin, the ESA dose over hemoglobin ratio (ESA/Hemoglobin) or the ESA resistance index (ERI). Third, we used a polytomous logistic regression model to compare groups of patients with no/low/high ESA dose and low/high hemoglobin statuses. Results Overall, 240 patients were included in the study. Mean age ± SD was 67.6 ± 16.0 years, 55.4% were men and 42.5% had diabetes mellitus. When compared with ESA treated patients, patients with no ESA had higher hemoglobin (mean 11.4 ± 1.1 versus 10.6 ± 1.2 g/dL; p <0.001), higher transferrin saturation (TSAT, 31.1 ± 16.3% versus 23.1 ± 11.5%; p < 0.001), less frequently an IV iron prescription (52.1 versus 65.7%, p = 0.04) and were more frequently treated with hemodiafiltration (53.5 versus 36.7%). In univariate analysis, IAA, IS or PCS plasma concentrations did not differ between the two groups. In the linear model, IAA plasma concentration was not associated with hemoglobin, but was negatively associated with ESA/Hb (p = 0.02; R = 0.18) and with the ERI (p = 0.03; R = 0.17). IS was associated with none of the three anemia parameters. PCS was positively associated with hemoglobin (p = 0.03; R = 0.14), but negatively with ESA/Hb (p = 0.03; R = 0.17) and the ERI (p = 0.02; R = 0.19). In multivariate analysis, the association of IAA concentration with ESA/Hb or ERI was not statistically significant, neither was the association of PCS with ESA/Hb or ERI. Identically, in the subgroup of 76 patients with no inflammation (CRP <5 mg/L) and no iron deficiency (TSAT >20%) linear regression between IAA, IS or PCS and any anemia parameter did not reach significance. In the third model, univariate analysis showed no intergroup significant differences for IAA and IS. Regarding PCS, the Low Hb/High ESA group had lower concentrations. However, when we compared PCS with the other significant characteristics of the five groups to the Low Hb/high ESA (our reference group), the polytomous logistic regression model didn’t show any significant difference for PCS. Conclusions In our study, using three different statistical models, we were unable to show any correlation between IAA, IS and PCS plasmatic concentrations and any anemia parameter in hemodialysis patients. Indolic uremic toxins and PCS have no or a very low effect on anemia parameters.
Collapse
Affiliation(s)
- Stanislas Bataille
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France. .,Phocean Nephrology Institute, Clinique Bouchard, 77 rue du Docteur Escat, 13006, Marseille, France. .,ELSAN, Clinique Bouchard, Marseille, France.
| | - Marion Pelletier
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - Marion Sallée
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.,UMR_S 1076, Vascular Research Center of Marseille, INSERM, Aix Marseille University, Marseille, France
| | - Yvon Berland
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - Nathalie McKay
- UMR_S 1076, Vascular Research Center of Marseille, INSERM, Aix Marseille University, Marseille, France
| | - Ariane Duval
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.,Association des Dialysés Provence et Corse, Marseille, France
| | - Stéphanie Gentile
- EA3279, unité de recherche santé publique et maladies chroniques, Aix-Marseille University, Marseille, France
| | - Yosra Mouelhi
- EA3279, unité de recherche santé publique et maladies chroniques, Aix-Marseille University, Marseille, France
| | - Philippe Brunet
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.,UMR_S 1076, Vascular Research Center of Marseille, INSERM, Aix Marseille University, Marseille, France
| | - Stéphane Burtey
- Centre de néphrologie et transplantation rénale, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.,UMR_S 1076, Vascular Research Center of Marseille, INSERM, Aix Marseille University, Marseille, France
| |
Collapse
|
76
|
Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L. Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. Clin Kidney J 2017; 10:578. [PMID: 28852498 PMCID: PMC5569950 DOI: 10.1093/ckj/sfx068] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Benjamin Brigant
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| | - Valérie Metzinger-Le Meuth
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France.,University Paris 13, Sorbonne Paris Cité, UFR SMBH, Bobigny, France
| | - Ziad A Massy
- Division of Nephrology, Ambroise Paré Hospital, Paris Ile de France Ouest (UVSQ) University, Boulogne Billancourt, France.,INSERM U1018, Centre de recherche en épidémiologie et santé des populations, Equipe 5, Villejuif, France
| | - Nathalie McKay
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Sophie Liabeuf
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| | - Marion Pelletier
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Marion Sallée
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Eléonore M'Baya-Moutoula
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| | - Pascale Paul
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Tilman B Drueke
- INSERM U1018, Centre de recherche en épidémiologie et santé des populations, Equipe 5, Villejuif, France
| | - Stéphane Burtey
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Laurent Metzinger
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| |
Collapse
|
77
|
Bataille S, Landrier JF, Astier J, Cado S, Sallette J, Serveaux M, Burtey S, Cohen J, Tournier C, Tourniaire F, Darmon P. Plasma Retinol Concentration Is Mainly Driven by Transthyretin in Hemodialysis Patients. J Ren Nutr 2017; 27:395-401. [PMID: 28688921 DOI: 10.1053/j.jrn.2017.05.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 04/11/2017] [Accepted: 05/02/2017] [Indexed: 11/11/2022] Open
Abstract
OBJECTIVE Micronutrients deficiencies in hemodialysis patients are due to low dietary intakes and intradialytic losses for hydrophilic micronutrients. Conversely, lipophilic nondialyzable compounds might accumulate because of a lack of elimination through renal metabolism or dialysis. Other compounds have complex metabolism: their concentration is not explained by these phenomenons. The aim of this study was to report plasma concentrations of lipophilic micronutrients in hemodialysis patients and to analyze if these concentrations were predictive of mortality. DESIGN The design was monocentric observational longitudinal study. SUBJECTS A total of 123 hemodialysis patients included in this observational study. MAIN OUTCOME MEASURE Plasma concentration of lipophilic micronutrients retinol and its two co-transporters transthyretin and retinol-binding protein 4, tocopherol, and carotenoids (α-carotene and β-carotene, β-cryptoxanthin, lycopene, lutein, and zeaxanthin), and all factors associated with 1-year mortality. RESULTS Within the 123 patients of the study, median age (interquartile range) was 77.5 (69.5-84.5) years and 58.5% were male. Median retinol plasma concentration was 4.07 (2.65-5.51) μmol/L, and 91.9% of patient had high plasma retinol concentrations. In monovariate analysis, retinol levels were inversely correlated with mortality (hazard ratio = 0.57 [0.45-0.72]; P < .001). This effect remained significant after adjustment with several parameters. Nevertheless, the correlation between retinol and mortality disappeared as soon as transthyretin was added in the statistical model, suggesting an effect of transthyretin as confusing bias. Median tocopherol plasma concentration was 34.8 (28.3-42.9) μmol/L and 72.4% of patients had high plasma tocopherol concentration. Neither tocopherol plasma levels nor carotenoids concentrations were correlated with death in multivariate analysis. CONCLUSIONS In hemodialysis patients, the correlation between retinol plasma concentration and mortality represents the nutritional status but not a direct biological effect of retinol. Retinol is only a surrogate predictor of mortality. It might not represent vitamin A levels, but likely the transthyretin level. Plasma retinol levels should be interpreted cautiously in hemodialysis patients.
Collapse
Affiliation(s)
- Stanislas Bataille
- Phocean Nephrology Institute, Marseille, France; Nephrology Department, Clinique Bouchard, ELSAN, Marseille, France; Nephrology Dialysis Renal Transplantation Center, APHM, CHU Conception, Marseille, France.
| | | | - Julien Astier
- NORT, Aix-Marseille Université, INRA, INSERM, Marseille, France
| | - Sylvie Cado
- Laboratoire Cerba, Saint-Ouen l'Aumône, France
| | | | - Marianne Serveaux
- Phocean Nephrology Institute, Marseille, France; Nephrology Department, Clinique Bouchard, ELSAN, Marseille, France
| | - Stéphane Burtey
- Nephrology Dialysis Renal Transplantation Center, APHM, CHU Conception, Marseille, France; Aix Marseille Université, Inserm, Vascular Research Center of Marseille UMR_S 1076, Marseille, France
| | | | | | | | - Patrice Darmon
- NORT, Aix-Marseille Université, INRA, INSERM, Marseille, France
| |
Collapse
|
78
|
Janus N, Launay-Vacher V, Juillard L, Deray G, Hannedouche T, Isnard-Rouchon M, Burtey S, Vanhille P, Ortiz JP, Janin G, Nicoud P, Touam M, Laville M. Course of chronic kidney disease in French patients. Clin Kidney J 2017. [PMID: 28638607 PMCID: PMC5469578 DOI: 10.1093/ckj/sfw092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background In 1998, a French survey showed that the referral of patients with chronic kidney disease to a nephrologist was delayed, resulting in many emergency initiations of dialysis. In 2009, the ORACLE study aimed to describe the renal course of dialysis patients from their first nephrology visit to their first dialysis session. Methods The ORACLE study was a multicentre retrospective study of all patients who started chronic dialysis. Data were collected at the first nephrology visit and at the first dialysis session. Results In total, 720 patients were included (69 centres). At the first nephrology visit, the mean Cockcroft–Gault (CG) indicator was 31.8 mL/min (22.7 in 1998) and 52.4% of patients (73% in 1998) had a CG <30. The mean time between the first nephrology visit and the first dialysis session was 48 months (35 months in 1998). Conclusion In 2009, most patients were referred a long time before dialysis initiation, which likely allowed them to benefit from the impact of nephrology care on early outcomes when on dialysis. However, 34.2% of the dialysis sessions were still initiated under emergency conditions.
Collapse
Affiliation(s)
- Nicolas Janus
- Service ICAR, Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France.,Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France
| | - Vincent Launay-Vacher
- Service ICAR, Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France.,Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Gilbert Deray
- Service ICAR, Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France.,Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France
| | | | | | - Stéphane Burtey
- Aix-Marseille Université Centre de Néphrologie, Hôpital de la Conception, Marseille, France
| | - Philippe Vanhille
- Néphrologie, Centre Hospitalier de Valenciennes, Valenciennes, France
| | | | | | - Philippe Nicoud
- Néphrologie, Hôpitaux du Pays du Mont-Blanc, Sallanches, France
| | | | - Maurice Laville
- Néphrologie, Hôpital Lyon Sud, INSERM U1060 CarMen, Université de Lyon, Pierre-Bénite, France
| |
Collapse
|
79
|
Weill O, Decramer S, Malcus C, Kassai B, Rouvet I, Ginhoux T, Crow YJ, Rieux-Laucat F, Soulas-Sprauel P, Pagnier A, Koné-Paut I, Piram M, Galeotti C, Samaille C, Reumaux H, Lanteri A, Dubois SM, Lefebvre H, Burtey S, Maurier F, Carbasse A, Lemelle I, Meinzer U, Despert V, Flodrops H, Fabien N, Ranchin B, Hachulla E, Bader-Meunier B, Belot A. Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus. Joint Bone Spine 2016; 84:589-593. [PMID: 28039062 DOI: 10.1016/j.jbspin.2016.12.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/21/2016] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Studies of early-onset systemic lupus erythematosus (SLE) have identified monogenic forms of the disease. The primary objective of this study was to compare the clinical and laboratory features of the first patients included in the GENIAL/LUMUGENE cohort to those reported in previous publications. The secondary objective was to determine whether subgroups with a distinctive pattern of clinical and biological features are seen in predominantly genetic forms of SLE. METHODS GENIAL/LUMUGENE is a French nationwide study of the clinical, immunological, and genetic features of juvenile-onset SLE (clinicaltrials.gov #NCT01992666). Clinical and laboratory data from the first 64 patients younger than 18 years who were included in the first part of the study were collected retrospectively. Predefined criteria were used to divide the patients into three subgroups: syndromic SLE (n=10) and familial SLE (n=12) - both presumed to have a strong genetic component - and other forms of early-onset SLE (n=42). RESULTS The predefined criteria for identifying subgroups based on knowledge of the clinical and epidemiological features of monogenic SLE showed a significantly younger age at onset in syndromic SLE (P<0.05) and a lower frequency of joint manifestations in familial SLE. CONCLUSIONS In this study, clinical and epidemiological data alone failed to identify a specific patient subgroup characterized by the same disease presentation or progression. This result may be related to the small sample size or indicate marked heterogeneity of juvenile-onset SLE. Genetic studies using new sequencing techniques in these patients might identify genetic factors responsible for marked phenotypic variability.
Collapse
Affiliation(s)
- Olivia Weill
- Service de Médecine Interne, Néphrologie, Rhumatologie-hypertension pédiatrique, Centre de Référence des maladies Rénales Rares du Sud Ouest, SORARE, Hôpital des enfants, CHU de Toulouse, 31059 Toulouse, France
| | - Stéphane Decramer
- Service de Médecine Interne, Néphrologie, Rhumatologie-hypertension pédiatrique, Centre de Référence des maladies Rénales Rares du Sud Ouest, SORARE, Hôpital des enfants, CHU de Toulouse, 31059 Toulouse, France
| | - Christophe Malcus
- Service d'Immunologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, 69437 Lyon, France
| | - Behrouz Kassai
- EPICIME-CIC 1407 de Lyon, Inserm, Service de Pharmacotoxicologie, CHU-Lyon, 69677 Bron, France; Université de Lyon, Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, 69622 Villeurbanne, France
| | - Isabelle Rouvet
- Centre de biotechnologie cellulaire et Biothèque, Groupe Hospitalier Est, Hospices Civils de Lyon, 69677 Bron, France
| | - Tiphanie Ginhoux
- EPICIME-CIC 1407 de Lyon, Inserm, Service de Pharmacotoxicologie, CHU-Lyon, 69677 Bron, France
| | - Yanick J Crow
- Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; INSERM UMR 1163, Laboratory of Neurogenetics and Neuroinflammation Paris Descartes University, Sorbonne-Paris-Cité, Institut Imagine, Hôpital Necker-Enfants-Malades, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Fredéric Rieux-Laucat
- INSERM UMR 1163, Laboratoire d'immunogénétique des maladies auto-immunes pédiatriques, Institut Imagine, 75015 Paris, France
| | - Pauline Soulas-Sprauel
- CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, UFR Sciences pharmaceutiques, Université de Strasbourg, 67200 Illkirch-Graffenstaden, France
| | - Anne Pagnier
- Service de rhumatologie pédiatrique, CHU de Grenoble, 38700 La Tronche, France
| | - Isabelle Koné-Paut
- Service de Rhumatologie Pédiatrique - Centre de Référence des maladies auto-inflammatoires de l'enfant (CeRéMAI), CHU de Bicêtre, APHP, Université Paris-Saclay, Université Paris Sud, 94276 Kremlin Bicêtre, France
| | - Maryam Piram
- Service de Rhumatologie Pédiatrique - Centre de Référence des maladies auto-inflammatoires de l'enfant (CeRéMAI), CHU de Bicêtre, APHP, Université Paris-Saclay, Université Paris Sud, 94276 Kremlin Bicêtre, France
| | - Caroline Galeotti
- Service de Rhumatologie Pédiatrique - Centre de Référence des maladies auto-inflammatoires de l'enfant (CeRéMAI), CHU de Bicêtre, APHP, Université Paris-Saclay, Université Paris Sud, 94276 Kremlin Bicêtre, France
| | | | - Héloïse Reumaux
- Unité de Néphrologie Pédiatriques, CHU de Lille, 59000 Lille, France
| | - Aurélia Lanteri
- Service de médecine interne, centre national de référence des maladies auto-immunes et systémiques rares, Hôpital Claude Huriez, FHU IMMNeNT, Université de Lille, 59037 Lille, France
| | - Sandrine Morell Dubois
- Service de médecine interne, centre national de référence des maladies auto-immunes et systémiques rares, Hôpital Claude Huriez, FHU IMMNeNT, Université de Lille, 59037 Lille, France
| | - Hélène Lefebvre
- Service de médecine interne, centre national de référence des maladies auto-immunes et systémiques rares, Hôpital Claude Huriez, FHU IMMNeNT, Université de Lille, 59037 Lille, France
| | - Stéphane Burtey
- Centre de néphrologie et de transplantation rénale, Aix-Marseille Université, Assistance publique-hôpitaux de Marseille, France
| | | | - Aurélia Carbasse
- Service de pédiatrie, CHU Montpellier, 34295 Montpellier, France
| | - Irène Lemelle
- Service d'Hémato-Onco Pédiatrie, CHRU Nancy, 54511 Vandoeuvre les Nancy, France
| | - Ulrich Meinzer
- Service de Pédiatrie Générale, Maladies Infectieuses et Médecine Interne Pédiatrique, Hôpital Robert Debré, APHP, INSERM, U1149, Centre de recherche sur l'inflammation, 75019 Paris, France
| | - Véronique Despert
- Service de Pédiatrie Grands Enfants-Adolescents, CHU Hôpital Sud, 35033 Rennes, France
| | - Hugues Flodrops
- Service de Pédiatrie, CHU La Réunion Site de Saint-Pierre, BP 350, 97448 Saint-Pierre, France
| | - Nicole Fabien
- Laboratoire d'autoimmunité, Service d'immunologie humorale, Hospices Civils de Lyon, CHLS, 69495 Pierre-Bénite, France
| | - Bruno Ranchin
- Immunologie et rhumatologie pédiatrique, Hôpital Necker, APHP, 75015 Paris, France
| | - Eric Hachulla
- Service de médecine interne, centre national de référence des maladies auto-immunes et systémiques rares, Hôpital Claude Huriez, FHU IMMNeNT, Université de Lille, 59037 Lille, France
| | - Brigitte Bader-Meunier
- Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; INSERM UMR 1163, Laboratory of Neurogenetics and Neuroinflammation Paris Descartes University, Sorbonne-Paris-Cité, Institut Imagine, Hôpital Necker-Enfants-Malades, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France; Service de néphrologie et rhumatologie pédiatrique, hôpital Femme-Mère-Enfant et université de Lyon 1, INSERM U1111, 69677 Bron, France
| | - Alexandre Belot
- Immunologie et rhumatologie pédiatrique, Hôpital Necker, APHP, 75015 Paris, France.
| |
Collapse
|
80
|
Metzinger-Le Meuth V, Burtey S, Maitrias P, Massy ZA, Metzinger L. microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs. Biochim Biophys Acta Mol Basis Dis 2016; 1863:337-345. [PMID: 27806914 DOI: 10.1016/j.bbadis.2016.10.027] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Revised: 10/04/2016] [Accepted: 10/28/2016] [Indexed: 02/07/2023]
Abstract
microRNAs comprise a novel class of endogenous small non-coding RNAs that have been shown to be implicated in both vascular damage and bone pathophysiology. Chronic kidney disease-mineral bone disorder (CKD-MBD) is characterized by vessel and bone damage secondary to progressive loss of kidney function. In this review, we will describe how several microRNAs have been implicated, in recent years, in cellular and animal models of CKD-MBD, and have been very recently shown to be deregulated in patients with CKD. Particular emphasis has been placed on the endothelial-specific miR-126, a potential biomarker of endothelial dysfunction, and miR-155 and miR-223, which play a role in both vascular smooth muscle cells and osteoclasts, with an impact on the vascular calcification and osteoporosis process. Finally, as these microRNAs may constitute useful targets to prevent or treat complications of CKD-MBD, we will discuss their potential as innovative drugs, describe how they could be delivered in a timely and specific way to vessels and bone by using the most recent techniques such as nanotechnology, viral vectors or CRISPR gene targeting.
Collapse
Affiliation(s)
- Valérie Metzinger-Le Meuth
- C.U.R.S, Laboratoire INSERM U1088, Chemin du Thil, Université de Picardie Jules Verne, 80025 Amiens Cedex 1, France; Université Paris 13, Sorbonne Paris Cité, UFR SMBH, 74 rue Marcel Cachin, 93017, Bobigny cedex, France
| | | | - Pierre Maitrias
- C.U.R.S, Laboratoire INSERM U1088, Chemin du Thil, Université de Picardie Jules Verne, 80025 Amiens Cedex 1, France; Department of Cardiovascular Surgery, Amiens University Hospital, France
| | - Ziad A Massy
- Division of Nephrology, Ambroise Paré Hospital, APHP, UVSQ University, INSERM U1018 team5, Paris, France
| | - Laurent Metzinger
- C.U.R.S, Laboratoire INSERM U1088, Chemin du Thil, Université de Picardie Jules Verne, 80025 Amiens Cedex 1, France.
| |
Collapse
|
81
|
Laforêt M, Von Kotze C, Perrin J, Brunet P, Dou L, Burtey S. La toxine urémique indoxyl sulfate induit l’expression du facteur tissulaire endothélial en conditions de flux par un mécanisme dépendant d’aryl hydrocarbon receptor. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
82
|
Pelletier M, Dou L, Sallée M, Bataille S, Brunet P, Burtey S. Activation d’aryl hydrocabon receptor et risque hémorragique dans une cohorte de patients hémodialysés. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
83
|
Sallée M, Mckay N, Dou L, Pelletier M, Bouchouareb D, Brunet P, Burtey S. Variabilité des taux de toxines urémiques. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
84
|
Perrin J, Gentile S, Tsimaratos M, Gareix F, Burtey S. La consultation de transition, un outil utile avant le transfert dans le monde des adultes ? Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
85
|
Legris T, Picard C, Todorova D, Lyonnet L, Laporte C, Dumoulin C, Nicolino-Brunet C, Daniel L, Loundou A, Morange S, Bataille S, Vacher-Coponat H, Moal V, Berland Y, Dignat-George F, Burtey S, Paul P. Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies. Front Immunol 2016; 7:288. [PMID: 27563301 PMCID: PMC4980873 DOI: 10.3389/fimmu.2016.00288] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 07/18/2016] [Indexed: 12/21/2022] Open
Abstract
Although kidney transplantation remains the best treatment for end-stage renal failure, it is limited by chronic humoral aggression of the graft vasculature by donor-specific antibodies (DSAs). The complement-independent mechanisms that lead to the antibody-mediated rejection (ABMR) of kidney allografts remain poorly understood. Increasing lines of evidence have revealed the relevance of natural killer (NK) cells as innate immune effectors of antibody-dependent cellular cytotoxicity (ADCC), but few studies have investigated their alloreactive potential in the context of solid organ transplantation. Our study aimed to investigate the potential contribution of the antibody-dependent alloreactive function of NK cells to kidney graft dysfunction. We first conducted an observational study to investigate whether the cytotoxic function of NK cells is associated with chronic allograft dysfunction. The NK-Cellular Humoral Activation Test (NK-CHAT) was designed to evaluate the recipient and antibody-dependent reactivity of NK cells against allogeneic target cells. The release of CD107a/Lamp1+ cytotoxic granules, resulting from the recognition of rituximab-coated B cells by NK cells, was analyzed in 148 kidney transplant recipients (KTRs, mean graft duration: 6.2 years). Enhanced ADCC responsiveness was associated with reduced graft function and identified as an independent risk factor predicting a decline in the estimated glomerular filtration rate over a 1-year period (hazard ratio: 2.83). In a second approach, we used the NK-CHAT to reveal the cytotoxic potential of circulating alloantibodies in vitro. The level of CD16 engagement resulting from the in vitro recognition of serum-coated allogeneic B cells or splenic cells was further identified as a specific marker of DSA-induced ADCC. The NK-CHAT scoring of sera obtained from 40 patients at the time of transplant biopsy was associated with ABMR diagnosis. Our findings indicate that despite the administration of immunosuppressive treatments, robust ADCC responsiveness can be maintained in some KTRs. Because it evaluates both the Fab recognition of alloantigens and Fc-driven NK cell activation, the NK-CHAT represents a potentially valuable tool for the non-invasive and individualized evaluation of humoral risk during transplantation.
Collapse
Affiliation(s)
- Tristan Legris
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception , Marseille , France
| | - Christophe Picard
- Établissement Français du Sang Alpes Méditerranée, Marseille, France; ADES UMR 7268, CNRS, EFS, Aix-Marseille Université, Marseille, France
| | - Dilyana Todorova
- UMR 1076, Vascular Research Center of Marseille, INSERM, Aix-Marseille University , Marseille , France
| | - Luc Lyonnet
- Hematology Unit, Assistance Publique des Hôpitaux de Marseille, Hopital de la Conception , Marseille , France
| | - Cathy Laporte
- Hematology Unit, Assistance Publique des Hôpitaux de Marseille, Hopital de la Conception , Marseille , France
| | - Chloé Dumoulin
- Hematology Unit, Assistance Publique des Hôpitaux de Marseille, Hopital de la Conception , Marseille , France
| | - Corinne Nicolino-Brunet
- Hematology Unit, Assistance Publique des Hôpitaux de Marseille, Hopital de la Conception , Marseille , France
| | - Laurent Daniel
- Laboratory for Anatomy, Pathology, Neuropathology, Hôpital de la Timone, Aix-Marseille University , Marseille , France
| | - Anderson Loundou
- Unité d'Aide méthodologique à la Recherche Clinique et Epidémiologique, DRRC, Assistance Publique Hôpitaux de Marseille , Marseille , France
| | - Sophie Morange
- Centre d'Investigation Clinique, Hôpital de la Conception , Marseille , France
| | - Stanislas Bataille
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception , Marseille , France
| | - Henri Vacher-Coponat
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception , Marseille , France
| | - Valérie Moal
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception , Marseille , France
| | - Yvon Berland
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception , Marseille , France
| | - Francoise Dignat-George
- UMR 1076, Vascular Research Center of Marseille, INSERM, Aix-Marseille University, Marseille, France; Hematology Unit, Assistance Publique des Hôpitaux de Marseille, Hopital de la Conception, Marseille, France
| | - Stéphane Burtey
- Nephrology Dialysis Renal Transplantation Center, Assistance Publique des Hôpitaux de Marseille, Hospital de la Conception, Marseille, France; UMR 1076, Vascular Research Center of Marseille, INSERM, Aix-Marseille University, Marseille, France
| | - Pascale Paul
- UMR 1076, Vascular Research Center of Marseille, INSERM, Aix-Marseille University, Marseille, France; Hematology Unit, Assistance Publique des Hôpitaux de Marseille, Hopital de la Conception, Marseille, France
| |
Collapse
|
86
|
Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L. Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. Clin Kidney J 2016. [PMID: 28643818 PMCID: PMC5469576 DOI: 10.1093/ckj/sfw060] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background MicroRNAs (miRNAs) are innovative and informative blood-based biomarkers involved in numerous pathophysiological processes. In this study and based on our previous experimental data, we investigated miR-126, miR-143, miR-145, miR-155 and miR-223 as potential circulating biomarkers for the diagnosis and prognosis of patients with chronic kidney disease (CKD). The primary objective of this study was to assess the levels of miRNA expression at various stages of CKD. Methods RNA was extracted from serum, and RT-qPCR was performed for the five miRNAs and cel-miR-39 (internal control). Results Serum levels of miR-143, -145 and -223 were elevated in patients with CKD compared with healthy controls. They were further increased in chronic haemodialysis patients, but were below control levels in renal transplant recipients. In contrast, circulating levels of miR-126 and miR-155 levels, which were also elevated in CKD patients, were lower in the haemodialysis group and even lower in the transplant group. Four of the five miRNA species were correlated with estimated glomerular filtration rate, and three were correlated with circulating uraemic toxins. Conclusions This exploratory study suggests that specific miRNAs could be biomarkers for complications of CKD, justifying further studies to link changes of miRNA levels with outcomes in CKD patients.
Collapse
Affiliation(s)
- Benjamin Brigant
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| | - Valérie Metzinger-Le Meuth
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France.,University Paris 13, Sorbonne Paris Cité, UFR SMBH, Bobigny, France
| | - Ziad A Massy
- Division of Nephrology, Ambroise Paré Hospital, Paris Ile de France Ouest (UVSQ) University, Boulogne Billancourt, France.,INSERM U1018, Centre de recherche en épidémiologie et santé des populations, Equipe 5, Villejuif, France
| | - Nathalie McKay
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Sophie Liabeuf
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| | - Marion Pelletier
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Marion Sallée
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Eléonore M'Baya-Moutoula
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| | - Pascale Paul
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Tilman B Drueke
- INSERM U1018, Centre de recherche en épidémiologie et santé des populations, Equipe 5, Villejuif, France
| | - Stéphane Burtey
- INSERM UMR_S 1076, Aix Marseille Université, INSERM UMR_S 1076, Marseille, France
| | - Laurent Metzinger
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1088, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (MP3C), CURS, Université Picardie Jules Verne, Amiens, France
| |
Collapse
|
87
|
Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P, Dussol B, Burtey S, Gondouin B. Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014. Blood Cancer J 2016; 6:e409. [PMID: 27015286 PMCID: PMC4817100 DOI: 10.1038/bcj.2016.17] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- M Laforet
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France
| | - N Jourde-Chiche
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France.,Vascular Research Center of Marseille, Faculté de Pharmacie, Aix-Marseille Université, Marseille, France
| | - F Haddad
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France
| | - M Sallee
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France.,Vascular Research Center of Marseille, Faculté de Pharmacie, Aix-Marseille Université, Marseille, France
| | - A M Stoppa
- Department of Hematology, Institut Paoli Calmette, Marseille, France
| | - P Brunet
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France.,Vascular Research Center of Marseille, Faculté de Pharmacie, Aix-Marseille Université, Marseille, France
| | - B Dussol
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France.,Vascular Research Center of Marseille, Faculté de Pharmacie, Aix-Marseille Université, Marseille, France
| | - S Burtey
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France.,Vascular Research Center of Marseille, Faculté de Pharmacie, Aix-Marseille Université, Marseille, France
| | - B Gondouin
- Centre de Nephrologie et Transplantation Rénale, Hopital La Conception, Marseille, France.,Vascular Research Center of Marseille, Faculté de Pharmacie, Aix-Marseille Université, Marseille, France
| |
Collapse
|
88
|
Dou L, Burtey S. The harmful effect of indoxyl sulfate on neovascularization in chronic kidney disease. Kidney Int 2016; 89:532-4. [DOI: 10.1016/j.kint.2015.12.030] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 12/15/2015] [Accepted: 12/16/2015] [Indexed: 01/16/2023]
|
89
|
Jourde-Chiche N, Whalen E, Gondouin B, Speake C, Gersuk V, Dussol B, Burtey S, Pascual V, Chaussabel D, Chiche L. Néphropathie lupique : la signature neutrophile identifiée par l’analyse modulaire du transcriptome sanguin est associée à sa survenue, sa sévérité et son pronostic. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
90
|
Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VLM, Lambeau G. Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. J Am Soc Nephrol 2015; 27:1517-33. [PMID: 26567246 DOI: 10.1681/asn.2014111061] [Citation(s) in RCA: 137] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2014] [Accepted: 08/06/2015] [Indexed: 12/16/2022] Open
Abstract
The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopathic membranous nephropathy. However, the value of anti-PLA2R1 antibody titers in predicting patient outcomes is unknown. Here, we screened serum samples from 50 patients positive for PLA2R1 for immunoreactivity against a series of PLA2R1 deletion mutants covering the extracellular domains. We identified reactive epitopes in the cysteine-rich (CysR), C-type lectin domain 1 (CTLD1), and C-type lectin domain 7 (CTLD7) domains and confirmed the reactivity with soluble forms of each domain. We then used ELISAs to stratify 69 patients positive for PLA2R1 by serum reactivity to one or more of these domains: CysR (n=23), CysRC1 (n=14), and CysRC1C7 (n=32). Median ELISA titers measured using the full-length PLA2R1 antigens were not statistically different between subgroups. Patients with anti-CysR-restricted activity were younger (P=0.008), had less nephrotic range proteinuria (P=0.02), and exhibited a higher rate of spontaneous remission (P=0.03) and lower rates of renal failure progression (P=0.002) and ESRD (P=0.01) during follow-up. Overall, 31 of 69 patients had poor renal prognosis (urinary protein/creatinine ratio >4 g/g or eGFR<45 ml/min per 1.73 m(2) at end of follow-up). High anti-PLA2R1 activity and epitope spreading beyond the CysR epitope were independent risk factors of poor renal prognosis in multivariable Cox regression analysis. Epitope spreading during follow-up associated with disease worsening (n=3), whereas reverse spreading from a CysRC1C7 profile back to a CysR profile associated with favorable outcome (n=1). We conclude that analysis of the PLA2R1 epitope profile and spreading is a powerful tool for monitoring disease severity and stratifying patients by renal prognosis.
Collapse
Affiliation(s)
- Barbara Seitz-Polski
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France; Service de Néphrologie, CHU de Nice, Université de Nice-Sophia Antipolis, France; Laboratoire d'Immunologie
| | - Guillaume Dolla
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France
| | - Christine Payré
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France
| | - Christophe A Girard
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France
| | - Joel Polidori
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France
| | - Kevin Zorzi
- Centre de Recherche Clinique, CHU de Nice, Université de Nice-Sophia Antipolis, France
| | - Eléonore Birgy-Barelli
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France
| | - Perrine Jullien
- Service de Néphrologie Dialyse Transplantation Rénale, CHU Hôpital Nord, Saint-Etienne, and Université de Saint-Etienne PRES Université de Lyon, Saint-Etienne, France
| | - Cécile Courivaud
- Service de Néphrologie Dialyse Transplantation Rénale, CHU de Besançon, France
| | - Thierry Krummel
- Service de Néphrologie et dialyse, CHU de Strasbourg, Strasbourg, France; and
| | | | | | - Stéphane Burtey
- Service de Néphrologie Dialyse Transplantation Rénale, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Conception, Marseille, France et UMR S1076, Université Aix-Marseille, France
| | - Christophe Mariat
- Service de Néphrologie Dialyse Transplantation Rénale, CHU Hôpital Nord, Saint-Etienne, and Université de Saint-Etienne PRES Université de Lyon, Saint-Etienne, France
| | - Vincent L M Esnault
- Service de Néphrologie, CHU de Nice, Université de Nice-Sophia Antipolis, France
| | - Gérard Lambeau
- Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS and Université de Nice-Sophia Antipolis, Valbonne Sophia-Antipolis, France;
| |
Collapse
|
91
|
Seitz-Polski B, Dolla G, Payré C, Tomas NM, Lochouarn M, Jeammet L, Mariat C, Krummel T, Burtey S, Courivaud C, Schlumberger W, Zorzi K, Benzaken S, Bernard G, Esnault VL, Lambeau G. Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy. Biochimie 2015; 118:104-15. [DOI: 10.1016/j.biochi.2015.08.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 08/14/2015] [Indexed: 11/25/2022]
|
92
|
Bobot M, Ghez C, Gondouin B, Sallée M, Fournier PE, Burtey S, Legris T, Dussol B, Berland Y, Souteyrand P, Tessonnier L, Cammilleri S, Jourde-Chiche N. Diagnostic performance of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography in cyst infection in patients with autosomal dominant polycystic kidney disease. Clin Microbiol Infect 2015; 22:71-77. [PMID: 26454062 DOI: 10.1016/j.cmi.2015.09.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Revised: 09/23/2015] [Accepted: 09/24/2015] [Indexed: 11/18/2022]
Abstract
Cyst infection is a common complication of autosomal dominant polycystic kidney disease (ADPKD). Diagnosis is challenging with standard imaging techniques. We aimed to evaluate the diagnostic performance of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG PET-CT) for the diagnosis of cyst infections among ADPKD patients, in comparison with computed tomography (CT) and magnetic resonance imaging (MRI). All APKD patients who underwent 18-FDG PET-CT for suspected cyst infection between 2006 and 2013 in a French teaching hospital were included. Diagnosis of cyst infection was retained a posteriori on an index of clinical suspicion. 18-FDG PET-CT findings were was considered to be positive in cases of cyst wall hypermetabolism. CT or MRI findings were were considered to be positive in cases of cyst wall thickening (and enhancement if contrast medium was injected) and infiltration of the adjacent fat. A control group of ADPKD patients with 18-FDG PET-CT performed for other reasons was included. Thirty-two 18-FDG PET-CT scans were performed in 24 ADPKD patients with suspected cyst infection. A diagnosis of cyst infection was retained in 18 of 32 cases: 14 with positive 18-FDG PET-CT findings, and four false negatives. There were no false positives and no hypermetabolism of cyst walls in nine ADPKD control patients. 18-FDG PET-CT had a sensitivity of 77%, a specificity of 100%, and a negative predictive value of 77%. 18-FDG PET-CT allowed a differential diagnosis in three patients. In contrast, CT had a sensitivity of 7% and a negative predictive value of 35% (p <0.001 vs. 18-FDG PET-CT). Only eight MRI scans were performed. The diagnostic performance of 18-FDG PET-CT is superior to that of CT in cyst infections, for comparable radiation doses and with no injection of nephrotoxic contrast medium, in ADPKD patients.
Collapse
Affiliation(s)
- M Bobot
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - C Ghez
- Aix-Marseille University, Department of Radiology, AP-HM Hopital Conception, Marseille, France
| | - B Gondouin
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - M Sallée
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - P E Fournier
- Aix-Marseille University, Department of Infectious Diseases, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, AP-HM Hopital Timone, Marseille, France
| | - S Burtey
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - T Legris
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - B Dussol
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - Y Berland
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France
| | - P Souteyrand
- Aix-Marseille University, Department of Radiology, AP-HM Hopital Conception, Marseille, France
| | - L Tessonnier
- Aix-Marseille University, Department of Radiology, AP-HM Hopital Conception, Marseille, France
| | - S Cammilleri
- Aix-Marseille University, Department of Nuclear Medicine, AP-HM Hopital Timone, Marseille, France
| | - N Jourde-Chiche
- Aix-Marseille University, Department of Nephrology, AP-HM Hopital Conception, Marseille, France.
| |
Collapse
|
93
|
Perrin J, Gondouin B, Appay R, Mallet S, Daniel L, Burtey S, Jourde- Chiche N. Une cause rare de néphrite aiguë immunoallergique granulomateuse. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
94
|
Decourt A, Bataille S, Bardin N, Frere C, Gondouin B, Jourde-Chiche N, Duval A, Sallée M, Brunet P, Burtey S. Les anticorps IgA anti-β2 glycoprotéine I ne sont pas un facteur indépendant de mortalité chez le patient en hémodialyse chronique. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
95
|
Laforet M, Jourde-Chiche N, Haddad F, Burtey S, Gondouin B. Évolution de la prise en charge du myélome multiple en néphrologie et impact sur la survie et l’indépendance de dialyse. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
96
|
Dou L, Addi T, Sallée M, Gondouin B, Jourde-Chiche N, Brunet P, Cerini C, Burtey S. Aryl hydrocarbon receptor est activé in vivo au cours de l’insuffisance rénale chronique. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
97
|
Duval-Sabatier A, Dou L, Sallée M, Pelletier M, Knidiri H, Burtey S, Brunet P. Comparaison de l’épuration de toxines en hémodialyse, HDF prédilution et HDF post-dilution. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
98
|
Mansour-Hendili L, Blanchard A, Le Pottier N, Roncelin I, Lourdel S, Treard C, González W, Vergara-Jaque A, Morin G, Colin E, Holder-Espinasse M, Bacchetta J, Baudouin V, Benoit S, Bérard E, Bourdat-Michel G, Bouchireb K, Burtey S, Cailliez M, Cardon G, Cartery C, Champion G, Chauveau D, Cochat P, Dahan K, De la Faille R, Debray FG, Dehoux L, Deschenes G, Desport E, Devuyst O, Dieguez S, Emma F, Fischbach M, Fouque D, Fourcade J, François H, Gilbert-Dussardier B, Hannedouche T, Houillier P, Izzedine H, Janner M, Karras A, Knebelmann B, Lavocat MP, Lemoine S, Leroy V, Loirat C, Macher MA, Martin-Coignard D, Morin D, Niaudet P, Nivet H, Nobili F, Novo R, Faivre L, Rigothier C, Roussey-Kesler G, Salomon R, Schleich A, Sellier-Leclerc AL, Soulami K, Tiple A, Ulinski T, Vanhille P, Van Regemorter N, Jeunemaître X, Vargas-Poussou R. Mutation Update of the CLCN5 Gene Responsible for Dent Disease 1. Hum Mutat 2015; 36:743-52. [PMID: 25907713 DOI: 10.1002/humu.22804] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 04/08/2015] [Indexed: 02/06/2023]
Abstract
Dent disease is a rare X-linked tubulopathy characterized by low molecular weight proteinuria, hypercalciuria, nephrocalcinosis and/or nephrolithiasis, progressive renal failure, and variable manifestations of other proximal tubule dysfunctions. It often progresses over a few decades to chronic renal insufficiency, and therefore molecular characterization is important to allow appropriate genetic counseling. Two genetic subtypes have been described to date: Dent disease 1 is caused by mutations of the CLCN5 gene, coding for the chloride/proton exchanger ClC-5; and Dent disease 2 by mutations of the OCRL gene, coding for the inositol polyphosphate 5-phosphatase OCRL-1. Herein, we review previously reported mutations (n = 192) and their associated phenotype in 377 male patients with Dent disease 1 and describe phenotype and novel (n = 42) and recurrent mutations (n = 24) in a large cohort of 117 Dent disease 1 patients belonging to 90 families. The novel missense and in-frame mutations described were mapped onto a three-dimensional homology model of the ClC-5 protein. This analysis suggests that these mutations affect the dimerization process, helix stability, or transport. The phenotype of our cohort patients supports and extends the phenotype that has been reported in smaller studies.
Collapse
Affiliation(s)
- Lamisse Mansour-Hendili
- Faculté de Médecine, Université Paris Descartes, Paris, France.,Assistance Publique-Hôpitaux de Paris, Service de Génétique, Hôpital Européen Georges Pompidou, Paris, France
| | - Anne Blanchard
- Faculté de Médecine, Université Paris Descartes, Paris, France.,INSERM, UMR970, Paris-Cardiovascular Research Center, Paris, France.,Assistance Publique-Hôpitaux de Paris, Centre d'investigation clinique, Hôpital Européen Georges Pompidou, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France
| | - Nelly Le Pottier
- Assistance Publique-Hôpitaux de Paris, Service de Génétique, Hôpital Européen Georges Pompidou, Paris, France
| | - Isabelle Roncelin
- Assistance Publique-Hôpitaux de Paris, Service de Génétique, Hôpital Européen Georges Pompidou, Paris, France
| | - Stéphane Lourdel
- Sorbonne Universités, UPMC Université, Paris, France.,INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMR S1138, Centre de Recherche des Cordeliers, CNRS ERL 8228, Paris, F-75006, France
| | - Cyrielle Treard
- Assistance Publique-Hôpitaux de Paris, Service de Génétique, Hôpital Européen Georges Pompidou, Paris, France.,INSERM, UMR970, Paris-Cardiovascular Research Center, Paris, France
| | - Wendy González
- Centro de Bioinformática y Simulación Molecular, Universidad de Talca, Talca, Chile
| | - Ariela Vergara-Jaque
- Centro de Bioinformática y Simulación Molecular, Universidad de Talca, Talca, Chile
| | - Gilles Morin
- Service de Génétique et Oncogénétique, Centre Hospitalier Universitaire Amiens Picardie, Amiens, France
| | - Estelle Colin
- Département de Biochimie et Génétique, LUNAM Angers, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Muriel Holder-Espinasse
- Département de Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.,Department of Clinical Genetics, Guy's Hospital, London, United Kingdom
| | - Justine Bacchetta
- Centre de Référence des Maladies Rénales Rares. Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France
| | - Véronique Baudouin
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Service de Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France
| | - Stéphane Benoit
- Service de Néphrologie, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Etienne Bérard
- Service de Néphrologie pédiatrique, Centre Hospitalier Universitaire de Nice, Nice, France
| | | | - Karim Bouchireb
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants-malades, Service de Néphrologie Pédiatrique, Paris, France
| | - Stéphane Burtey
- VRCM, centre de néphrologie et transplantation rénale, Aix-Marseille Université, Marseille, France
| | - Mathilde Cailliez
- Assistance Publique Hôpitaux de Marseille, Unité de Néphrologie Pédiatrique, Hôpital La Timone, Marseille, France
| | - Gérard Cardon
- Service de Néphrologie, Centre Hospitalier de Douai, Douai, France
| | - Claire Cartery
- Assistance Publique-Hôpitaux de Paris, Service de Néphrologie et dialyse, Hôpital Tenon, Paris, France
| | - Gerard Champion
- Département de Pédiatrie, LUNAM Angers, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Dominique Chauveau
- Centre Hospitalier Universitaire de Toulouse, Département de Néphrologie et Transplantation d'organes, Hôpital Rangueil, Toulouse, France
| | - Pierre Cochat
- Centre de Référence des Maladies Rénales Rares. Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France
| | - Karin Dahan
- Département de Génétique Humaine, Institut de Pathologie et de Génétique, Gosselies, Belgium
| | - Renaud De la Faille
- Service de Néphrologie Transplantation Dialyse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | | | - Laurenne Dehoux
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Service de Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France
| | - Georges Deschenes
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Service de Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France
| | - Estelle Desport
- Service de Néphrologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Olivier Devuyst
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.,Institute of Physiology, University of Zurich, Zurich, Switzerland
| | - Stella Dieguez
- Nefrologia Infantil, Hospital General de Agudos Dr. Teodoro Álvarez, Buenos Aires, Argentina
| | - Francesco Emma
- Division of Nephrology and Dialysis, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy
| | - Michel Fischbach
- Service de Pédiatrie, Centre Hospitalier Universitaire Hautepierre, Strasbourg, France
| | - Denis Fouque
- Departement de Néphrology, Centre Hospitalier Universitaire Lyon Sud, Lyon, France
| | - Jacques Fourcade
- Service de Néphrology, Centre Hospitalier de Chambery, Chambery, France
| | - Hélène François
- Assistance Publique-Hôpitaux de Paris, Hôpital Kremlin Bicêtre, Service de Néphrologie, Le Kremlin-Bicêtre, France
| | - Brigitte Gilbert-Dussardier
- Centre Hospitalier Universitaire de Poitiers, Service de Génétique, EA 3808, Université de Poitiers, Poitiers, France
| | - Thierry Hannedouche
- Hôpitaux Universitaires de Strasbourg, Service de Néphrologie et Faculté de Médecine, Université de Strasbourg, Strasbourg, France
| | - Pascal Houillier
- Faculté de Médecine, Université Paris Descartes, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMR S1138, Centre de Recherche des Cordeliers, CNRS ERL 8228, Paris, F-75006, France.,Assistance Publique Hôpitaux de Paris, Département de Physiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Hassan Izzedine
- Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service de Néphrologie, Paris, France
| | - Marco Janner
- Department of Paediatric Endocrinology, Diabetology and Metabolism, University of Berne Children's Hospital, Berne, Switzerland
| | - Alexandre Karras
- Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Néphrologie, Paris, France
| | - Bertrand Knebelmann
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants-malades, Service de Néphrologie adulte, Paris, France
| | - Marie-Pierre Lavocat
- Département de Pédiatrie, Centre Hospitalier Universitaire de Saint Etienne, Hôpital Nord, Saint Etienne, France
| | - Sandrine Lemoine
- Hospices Civils de Lyon, Service d'Exploration Fonctionnelle Rénale, Hôpital Edouard-Herriot, Lyon, France
| | - Valérie Leroy
- Hôpital Jeanne de Flandre, Service de Néphrologie Pédiatrique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Chantal Loirat
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Service de Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France
| | - Marie-Alice Macher
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Service de Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France
| | | | - Denis Morin
- Unité de Néphrologie Pédiatrique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Patrick Niaudet
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants-malades, Service de Néphrologie Pédiatrique, Paris, France
| | - Hubert Nivet
- Service de Néphrologie, Centre Hospitalier Universitaire de Tours, Tours, France
| | - François Nobili
- Unité de Néphrologie Pédiatrie, Besançon, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Robert Novo
- Hôpital Jeanne de Flandre, Service de Néphrologie Pédiatrique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Laurence Faivre
- Centre de Génétique, Centre Hospitalier Universitaire de Dijon, Dijon, France
| | - Claire Rigothier
- Service de Néphrologie Transplantation Dialyse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | | | - Remi Salomon
- Faculté de Médecine, Université Paris Descartes, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants-malades, Service de Néphrologie Pédiatrique, Paris, France
| | - Andreas Schleich
- Institute of Nephrology Statspital Waid Zuerich, Zuerich, Switzerland
| | - Anne-Laure Sellier-Leclerc
- Centre de Référence des Maladies Rénales Rares. Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France
| | | | - Aurélien Tiple
- Centre Hospitalier Universitaire Gabriel-Montpied Service de Néphrologie, Clermont-Ferrand, France
| | - Tim Ulinski
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France.,Assistance Publique-Hôpitaux de Paris, Service de Néphrologie et Transplantation Rénale, Hôpital Trousseau, Paris, France
| | - Philippe Vanhille
- Centre Hospitalier de Valenciennes, Service de Néphrologie et Médecine Interne, Valenciennes, France
| | - Nicole Van Regemorter
- Université Libre de Bruxelles, Hôpital Erasme Département de Génétique Médicale, Brussels, Belgium
| | - Xavier Jeunemaître
- Faculté de Médecine, Université Paris Descartes, Paris, France.,Assistance Publique-Hôpitaux de Paris, Service de Génétique, Hôpital Européen Georges Pompidou, Paris, France.,INSERM, UMR970, Paris-Cardiovascular Research Center, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France
| | - Rosa Vargas-Poussou
- Assistance Publique-Hôpitaux de Paris, Service de Génétique, Hôpital Européen Georges Pompidou, Paris, France.,INSERM, UMR970, Paris-Cardiovascular Research Center, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Paris, France
| |
Collapse
|
99
|
Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. ACTA ACUST UNITED AC 2015; 63:136-43. [DOI: 10.1016/j.patbio.2015.03.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 03/03/2015] [Indexed: 12/21/2022]
|
100
|
Affiliation(s)
- P Souteyrand
- APHM, Conception, Service d'Imagerie Médicale, 13005 Marseille, France; Aix-Marseille University, LIIE-Laboratoire d'Imagerie Interventionnelle Expérimentale, EA 4264, 13005 Marseille, France.
| | - S Burtey
- Aix-Marseille University, UMRS-1076, VRCM, Marseille, France; Centre de néphrologie et transplantation rénale, APHM, Marseille, France
| | - F Barlesi
- Aix-Marseille University, APHM, Multidisciplinary Oncology and Therapeutic Innovations department and Inserm U911 CRO2, Marseille, France
| |
Collapse
|